MAO-B Inhibitors for Parkinson's Disease — Investment Landscape Analysis

Migration, Crosslink

📖

MAO-B Inhibitors for Parkinson's Disease — Investment Landscape Analysis

active

wiki page Created: 2026-04-02T07:19:35 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-investment-mao-b-inhibitors

📖 Wiki Page

investment916 wordssynced 2026-04-02

Overview

flowchart TD investment_mao_b_inhibitors["MAO-B Inhibitors for Parkinsons Disease Inves"] style investment_mao_b_inhibitors fill:#4fc3f7,stroke:#333,color:#000 investment_mao_b_inh_0["Market Overview"] investment_mao_b_inhibitors -->|"includes"| investment_mao_b_inh_0 style investment_mao_b_inh_0 fill:#81c784,stroke:#333,color:#000 investment_mao_b_inh_1["Approved MAO-B Inhibitors"] investment_mao_b_inhibitors -->|"includes"| investment_mao_b_inh_1 style investment_mao_b_inh_1 fill:#ef5350,stroke:#333,color:#000 investment_mao_b_inh_2["Market Drivers"] investment_mao_b_inhibitors -->|"includes"| investment_mao_b_inh_2 style investment_mao_b_inh_2 fill:#ffd54f,stroke:#333,color:#000 investment_mao_b_inh_3["Pipeline Analysis"] investment_mao_b_inhibitors -->|"includes"| investment_mao_b_inh_3 style investment_mao_b_inh_3 fill:#ce93d8,stroke:#333,color:#000 investment_mao_b_inh_4["Clinical Trials"] investment_mao_b_inhibitors -->|"includes"| investment_mao_b_inh_4 style investment_mao_b_inh_4 fill:#4fc3f7,stroke:#333,color:#000 investment_mao_b_inh_5["Next-Generation Approaches"] investment_mao_b_inhibitors -->|"includes"| investment_mao_b_inh_5 style investment_mao_b_inh_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Monoamine oxidase type B (MAO-B) inhibitors represent one of the most established and commercially successful therapeutic classes in Parkinson's disease (PD) treatment. Three FDA-approved drugs—selegiline, rasagiline, and safinamide—generate combined annual revenues exceeding $500 million globally. The class offers neuroprotective potential beyond symptomatic relief, making it attractive for disease-modifying therapy development. This investment landscape analyzes the current market, pipeline, research gaps, and investment opportunities in the MAO-B inhibitor space.

Market Overview

Approved MAO-B Inhibitors

| Drug | Approval Year | Manufacturer | Annual Revenue (Est.) | Key Markets | [@selegiline2021]
|------|---------------|--------------|----------------------|-------------| [@safinamide2020]
| Selegiline (Eldepryl/ Zelapar) | 1989/2003 | Somerset Pharmaceuticals | ~$50M | US, EU | [@maob2023]
| Rasagiline (Azilect) | 2006 | Teva Pharmaceuticals | ~$300M | Global | [@clinicaltrialsgov]
| Safinamide (Xadago) | 2017 | Zambon/Supernus Pharmaceuticals | ~$150M | US, EU, Japan | [@nih]

The global MAO-B inhibitor market is valued at approximately $600-700 million annually, with steady growth driven by: (1) increasing PD prevalence, (2) earlier treatment initiation, and (3) combination therapy adoption. [@parkinsons]

Market Drivers

Aging population: Global PD cases projected to reach 12 million by 2040
Disease-modifying potential: MAO-B inhibitors shown to reduce oxidative stress and may slow disease progression
Combination therapy: Growing use with levodopa and dopamine agonists
Generic competition: Patent expirations creating value opportunities for novel formulations

Pipeline Analysis

Clinical Trials

As of 2026, ClinicalTrials.gov lists approximately 45 active or completed trials involving MAO-B inhibitors: [@teva]

Phase 3: 8 trials (mostly combination studies with levodopa)
Phase 2: 15 trials (neuroprotection, non-motor symptoms)
Phase 1: 12 trials (novel compounds, formulations)

Next-Generation Approaches

Novel selective MAO-B inhibitors:

T-2268 (Mitsubishi Tanabe) — Phase 2 for PD
sembragiline (Evonik) — Phase 2 for Alzheimer's with PD biomarkers

Dual-targeting compounds:

MAO-B + dopamine receptor modulators
MAO-B + COMT inhibitor combinations

Improved formulations:

Transdermal selegiline (available, expanding)
Extended-release rasagiline formulations
Subcutaneous safinamide delivery

Repositioned compounds:

Selegiline for Alzheimer's disease (10+ trials)
Rasagiline for ALS (Phase 2)

Research Institutions

Key research groups advancing MAO-B therapeutics:

University of Pennsylvania: MAO-B in PD progression biomarkers
University of Oxford: Neuroprotection mechanisms
Karolinska Institute: Selegiline long-term outcomes
Parkinson's UK Drug Discovery Unit: Novel MAO-B inhibitor development

NIH Funding Trends

Historical Funding

| Fiscal Year | MAO-B Related Grants | Total Funding |
|-------------|---------------------|--------------|
| FY2020 | 12 grants | ~$4.2M |
| FY2021 | 14 grants | ~$4.8M |
| FY2022 | 11 grants | ~$3.9M |
| FY2023 | 13 grants | ~$4.5M |
| FY2024 | 15 grants | ~$5.1M |

NIH funding for MAO-B research has remained relatively stable at $4-5 million annually, with increasing focus on: (1) biomarkers for neuroprotection, (2) combination therapies, and (3) novel drug delivery systems.

Funding Gaps

Limited Phase 3 neuroprotection trials (most funding Phase 1/2)
Insufficient research on MAO-B in non-PD neurodegenerative conditions
Underfunded comparative effectiveness studies
Lack of biomarkers for treatment response prediction

Competitive Landscape

Key Players

Teva Pharmaceuticals: Dominant player with Azilect (rasagiline), pursuing next-generation formulations

Zambon/Supernus: Safinamide (Xadago) with patent protection through 2028

Somerset Pharmaceuticals: Generic selegiline and transdermal formulations

Mitsubishi Tanabe: Novel MAO-B inhibitors in development

Generic Impact

Selegiline: Generic since 2014
Rasagiline: Generic since 2022 (US)
Safinamide: Patent expiry approaching (2028)

Generic competition has significantly impacted revenue but created opportunities for: (1) novel formulations, (2) combination products, and (3) geographic expansion.

Research Gaps

Unmet Needs

Disease modification: No MAO-B inhibitor has demonstrated definitive disease-modifying effects in large trials

Biomarkers: Lack of validated biomarkers for neuroprotection

Combination therapy optimization: Optimal sequencing and dosing unclear

Non-motor symptoms: Limited data on cognitive, autonomic benefits

Early intervention: No approved use in prodromal PD

Neuroprotection trials: Cost and duration barriers

Investment Opportunities

Novel selective inhibitors: Better safety/tolerability profiles

Dual-action compounds: MAO-B + additional targets

Biomarker development: Companion diagnostics for neuroprotection

Formulation innovations: Long-acting, transdermal, inhaled delivery

Combination products: Fixed-dose combinations with levodopa/COMT inhibitors

Repositioning: ALS, Alzheimer's, depression (selegiline)

Investment Recommendations

High-Value Targets

| Opportunity | Rationale | Risk Level |
|-------------|-----------|------------|
| Novel MAO-B inhibitors with improved selectivity | Differentiation, patent protection | Medium |
| Biomarker companies targeting MAO-B pathways | Companion diagnostic potential | Medium-High |
| Combination therapy developers | Market expansion, premium pricing | Low-Medium |
| Drug delivery technologies | Life-cycle management | Medium |

Market Projections

2025-2030: 4-6% CAGR driven by PD prevalence and combination therapy adoption
2030-2035: Potential disease-modifying breakthrough could accelerate growth to 8-10% CAGR
Key uncertainties: Generic erosion, competing disease-modifying approaches ([alpha-synuclein](/proteins/alpha-synuclein), LRRK2)

Cross-Links

[MAO-B Inhibitors Treatment Page](/therapeutics/mao-b-inhibitors)
[Parkinson's Disease Investment Landscape](/diseases/parkinsons-disease-investment-landscape)
[Dopamine Therapeutics](/investment/dopamine-therapeutics)
[Oxidative Stress Mechanisms](/mechanisms/oxidative-stress)
[Neuroinflammation Therapeutics](/therapeutics/neuroinflammation-therapeutics)
[Alpha-Synuclein Targeting Therapies](/therapeutics/alpha-synuclein-targeting-therapies)
[Levodopa Therapy](/therapeutics/levodopa)
[Parkinson's Disease](/diseases/parkinsons-disease)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Rasagiline: A Review of its Use in Parkinson's Disease (CNS Drugs, 2022) (2022)](https://doi.org/10.1007/s40263-022-00927-z)

[Unknown, Selegiline in Parkinson's Disease: Mechanisms and Clinical Outcomes (J Neural Transm, 2021) (2021)](https://doi.org/10.1007/s00702-021-02338-w)

[Unknown, Safinamide: Pharmacology and Clinical Efficacy in Parkinson's Disease (Expert Opin Pharmacother, 2020) (2020)](https://doi.org/10.1080/14656566.2020.1721464)

[Unknown, MAO-B Inhibitors and Neuroprotection: Current Evidence (Neurobiology of Disease, 2023) (2023)](https://doi.org/10.1016/j.nbd.2023.105894)

Unknown, ClinicalTrials.gov MAO-B Inhibitor Trials Overview (n.d.)

Unknown, NIH RePORTER MAO-B Research Funding Data (n.d.)

Unknown, Parkinson's Disease Foundation Epidemiology Statistics (n.d.)

Unknown, Teva Azilect Product Information (n.d.)

Pathway Diagram

The following diagram shows the key molecular relationships involving MAO-B Inhibitors for Parkinson's Disease — Investment Landscape Analysis discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

investment-mao-b-inhibitors

▸Metadataorigin_type: v1_polymorphic_backfill

slug	investment-mao-b-inhibitors
kg_node_id	None
entity_type	investment
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-2e4c68c180cc
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'investment-mao-b-inhibitors'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

379

Outgoing

380

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

MAO-B Inhibitors for Parkinson's Disease — Investment Landscape Analysis

Overview

Overview

Market Overview

Approved MAO-B Inhibitors

Market Drivers

Pipeline Analysis

Clinical Trials

Next-Generation Approaches

Research Institutions

NIH Funding Trends

Historical Funding

Funding Gaps

Competitive Landscape

Key Players

Generic Impact

Research Gaps

Unmet Needs

Investment Opportunities

Investment Recommendations

High-Value Targets

Market Projections

Cross-Links

See Also

External Links

References

Pathway Diagram

💬 Discussion